Resource Networks for Protein Polymorphisms in Alzheimers Disease and its Related Dementias (AD/ADRD) (U24 Clinical Trial Not Allowed) | RFA AG 22 030

Frequently Asked Questions (FAQs)

What is the NIH funding opportunity RFA-AG-22-030?

RFA-AG-22-030 is an NIH funding opportunity that supports the creation of cooperative, shared research infrastructure focused on misfolded protein polymorphisms in Alzheimers disease (AD) and Alzheimers disease-related dementias (AD/ADRD). The goal is to build community-serving resource networks that improve standardization and reproducibility across the field.

What is the main purpose of this program?

The central purpose is to establish resource networks that can reliably produce, characterize, standardize, and distribute key pathogenic protein species used in AD/ADRD research, specifically seeds, oligomers, and fibrils. The program aims to reduce variability between labs and make results more comparable across institutions.

What type of NIH award mechanism is used?

This opportunity uses a U24 Cooperative Agreement. That mechanism is intended for building and operating a community-serving resource with substantial NIH involvement and coordination, rather than supporting a single labs independent research project.

What does "Cooperative Agreement (U24)" mean in practical terms?

Based on the description provided, a U24 Cooperative Agreement indicates that NIH expects substantial involvement and coordination in how the resource is built and operated. The focus is on shared infrastructure and services for the broader research community, not an investigator-driven project limited to one lab.

Are clinical trials allowed under this FOA?

No. The FOA is explicitly marked "Clinical Trial Not Allowed." The work is centered on resource development, standardization, characterization, and distribution activities rather than prospective clinical interventions.

If clinical trials are not allowed, what kinds of activities are emphasized?

The opportunity emphasizes building and operating shared capabilities such as production protocols, characterization pipelines, quality control, documentation, standard-setting, and distribution processes for misfolded protein materials used by AD/ADRD researchers.

Which proteins are specifically highlighted in the opportunity?

The FOA is particularly focused on polymorph variation in three proteins strongly implicated in AD/ADRD: amyloid beta (Abeta), alpha-synuclein, and tau.

What are misfolded protein polymorphs (or strains) in the context of this program?

In this program, polymorphs (sometimes described as strains) refer to different structural forms of misfolded proteins. The FOA notes that these forms may differ in toxicity, seeding capacity, spreading behavior, and pathological signatures, and may help explain patient-to-patient differences.

Why is the program focused on standardizing seeds, oligomers, and fibrils?

The FOA highlights that these materials can be difficult to prepare consistently from lab to lab, and even small differences in preparation methods can alter biological behavior and lead to irreproducible findings. Standardized, quality-controlled preparations are intended to reduce that variability.

What problem is this program trying to solve for the research community?

It aims to address inconsistent preparation and characterization of pathogenic protein species across laboratories, which can create variability and irreproducible results. By providing well-defined, shared reagents and harmonized methods, the program is designed to strengthen comparability and reproducibility across studies.

What kinds of deliverables or outputs are expected from a resource network?

Beyond making reagents available, the FOA emphasizes establishing standards and improving community-wide consistency. This implies developing rigorous production protocols, batch-to-batch quality assessment, strong documentation, and reliable distribution processes, along with coordination that helps researchers converge on shared definitions and measurement practices for polymorph identity and activity.

Does the opportunity support distribution of materials to other investigators?

Yes. A core element described is the ability to distribute standardized reagents (such as seeds, oligomers, and fibrils) to other investigators so studies across institutions can use comparable, quality-controlled materials.

How does the FOA describe the role of analytics and characterization?

The program envisions developing and applying emerging analytic tools capable of distinguishing polymorphs and linking them to patient-to-patient differences. It also highlights characterization pipelines and reference materials to better interpret relationships between polymorph identity, biochemical or structural variation, and disease-relevant phenotypes.

Is this opportunity intended to fund a single labs research project?

No. The description states that the award is intended for building and operating a community-serving resource with coordination and NIH involvement, rather than supporting a single labs independent research project.

Who is eligible to apply?

Eligibility is broad and includes government, academia, nonprofit, and industry. Eligible applicants listed include state, county, city, township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations with and without 501(c)(3) status; for-profit organizations (other than small businesses) and small businesses; public housing authorities/Indian housing authorities; and Native American tribal governments (federally recognized) and tribal organizations (other than federally recognized governments).

Are non-U.S. (foreign) entities eligible?

Yes. The FOA explicitly includes non-U.S. (foreign) entities among the eligible categories listed in the provided information.

Are U.S. territories or possessions eligible?

Yes. The FOA includes U.S. territories or possessions among the eligible categories listed in the provided information.

Does the FOA mention specific institution types like HBCUs or Hispanic-serving Institutions?

Yes. The listed eligible categories include Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, Hispanic-serving Institutions, Historically Black Colleges and Universities, and Tribally Controlled Colleges and Universities, among others.

Are faith-based or community-based organizations eligible?

Yes. Faith-based or community-based organizations are included in the additional eligible categories highlighted in the provided information.

Can federal agencies apply?

Yes. Eligible federal agencies are included among the additional eligible categories listed.

Which agency sponsors this funding opportunity?

The sponsoring agency is the National Institutes of Health (NIH).

What is the program category and CFDA number listed?

The activity falls under the Health category, and the CFDA number provided is 93.866.

What is the application closing date mentioned?

The source information lists an original closing date of January 10, 2022.

Does the provided information state an award ceiling or the expected number of awards?

No. The provided excerpt does not list an award ceiling or an expected number of awards.

What is meant by "resource networks" in this opportunity?

In the context provided, resource networks are coordinated, community-serving infrastructures that create dependable and standardized misfolded protein resources and harmonized methods. The intent is to provide shared capabilities that many investigators can use, rather than isolated efforts.

How does this opportunity aim to improve reproducibility across AD/ADRD studies?

It aims to improve reproducibility by providing well-defined, quality-controlled protein preparations and by promoting common standards, reference materials, and shared characterization pipelines. This helps reduce differences caused by lab-specific preparation methods and measurement practices.

What longer-term scientific goal is described?

A long-term goal described is to develop and apply analytic tools that distinguish misfolded protein polymorphs and link them directly to patient-to-patient differences, helping clarify how specific polymorphs relate to disease mechanisms, heterogeneity, and pathology.